RNS Number : 4394J
SkinBioTherapeutics PLC
27 April 2022
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Confirmation of Directorate Appointments
27 April 2022 -
SkinBioTherapeutics plc (AIM: SBTX), a life Science business focusing on skin health, today announces that further to the announcement of 28 March 2022, the proposed appointments of Manprit Singh Randhawa as full time Chief Financial Officer (CFO) and Danielle Bekker as non-executive director have been approved by the Company's AIM Nominated Adviser.
Danielle Bekker will commence in the role of non-executive director immediately while Manprit Randhawa will commence his appointment by 1 June 2022. Doug Quinn will continue as CFO until Manprit is appointed, stepping down from the board with effect 1 May 2022.
Manprit Singh Randhawa, aged 39, holds or has held in the past 5 years the following directorships and partnerships:
|
Current
|
Past five years
|
|
Juniper Education Group Limited
Juniper Education Holdco Limited
Juniper Education Holdings Limited
Juniper Education Limited
Juniper Education Midco Limited
Juniper Education Services Limited
Klik Limited
Maze Education Limited
Optimum Reports Ltd
Prime Principle Limited
Pupilasset Ltd
Target Tracker Limited
Financial Services 4 Schools Limited
The Concentric Curriculum Limited
Sisra Limited
Juniper Education Newco Limited
Jane IT Systems Limited
Primarysite Limited
E4Education Limited
E4Education Holdings Limited
|
Bidco Oasis Limited
Oval (2304) Limited
Smoothwall Limited
Topco Oasis Limited
Safeguard Software Limited
Onbone Sports Limited
Onbone Ltd
|
Danielle Bekker, aged 45, holds or has held in the past 5 years the following directorships and partnerships:
|
Current
|
Past five years
|
|
Good Living Brew Co Limited
Marmalade Consulting Limited
Flexipro Employee Resources (Pty) Ltd
|
n/a
|
Save as disclosed above, no further information is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc
Stuart J
. Ashman, CEO
Doug Quinn, CFO
|
Tel: +44 (0) 161 468 2760
|
|
Cenkos Securities Plc
(Nominated Adviser & Broker)
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson, Dale Bellis (Sales)
|
Tel: +44 (0) 20 7397 8900
|
|
Instinctif Partners (financial press)
Melanie Toyne-Sewell / Tim Field / Jonjo Cordey
|
Tel: +44 (0) 20 7457 2020
[email protected]
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:
www.skinbiotix.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
BOAEAXLKAFLAEFA